Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

lannett company, inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: - with urinary retention [see warnings and precautions ( 5.2 ) ] , - with gastric retention [see warnings and precautions ( 5.3 )] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions ( 5.5 )] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions  ( 6.2 )] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregna

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

sunshine lake pharma co., ltd. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate is contraindicated in patients with: - urinary retention [see warnings and precautions ( 5.2)] , - gastric retention [see warnings and precautions ( 5.3)] , - uncontrolled narrow-angle glaucoma [see warnings and precautions ( 5.5)] , and - in patients who have demonstrated hypersensitivity to the drug [see adverse reactions ( 6.2)] . pregnancy category c there are no adequate and well-controlled studies in pregnant women. reproduction studies have been performed in mice, rats and rabbits. after oral administration of 14 c-solifena

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva b.v. - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva b.v. - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Irska - engleski - HPRA (Health Products Regulatory Authority)

aristo pharma gmbh - solifenacin succinate - film-coated tablet - solifenacin

Irska - engleski - HPRA (Health Products Regulatory Authority)

aristo pharma gmbh - solifenacin succinate - film-coated tablet - solifenacin

Irska - engleski - HPRA (Health Products Regulatory Authority)

accord healthcare limited - solifenacin succinate - film coated tablet - 5 milligram - solifenacin

Irska - engleski - HPRA (Health Products Regulatory Authority)

accord healthcare limited - solifenacin succinate - film coated tablet - 10 milligram - solifenacin

Malta - engleski - Medicines Authority

portfarma ehf. borgartúni 26, is – 105 reykjavík, iceland - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - engleski - Medicines Authority

portfarma ehf. borgartúni 26, is – 105 reykjavík, iceland - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals